Brussels (Belgium) & Atlanta, Georgia (U.S.) – May 20 2019: UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application for the company’s newest anti-epileptic drug (AED) Nayzilam…Original Article
FDA Approves Nayzilam (midazolam) Nasal Spray to Treat Seizure Clusters
